<\/p>\n
Endace<\/strong> er en oral tablet fra Cipla, der indeholder megestrol acetate<\/strong> p\u00e5 40 mg and 160 mg<\/strong> — a synthetic progestin used as appetite stimulant<\/strong> in cancer cachexia and HIV-related anorexia, and as palliative endocrine therapy in advanced hormone-receptor-positive breast cancer and endometrial cancer. Standard appetite-stimulant dose: 400–800 mg\/day<\/strong> (typically 800 mg\/day in cancer cachexia). Onset of appetite improvement at 1–2 weeks; weight gain (mostly fat, not muscle) at 4–6 weeks. Increased venous thromboembolism risk<\/strong> — caution in immobilised cancer patients; consider DVT prophylaxis. Other warnings: adrenal suppression with prolonged use (mineralocorticoid effect), hyperglycaemia, fluid retention.<\/p>\n<\/div>\n \ud83d\udce6 Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.<\/p>\n Endace is an oral tablet from Cipla containing megestrol acetate<\/strong> (40 mg and 160 mg). Megestrol is a synthetic progestin with potent appetite-stimulant effects. The dominant modern use is as supportive care for cancer cachexia<\/strong> — the involuntary weight loss that affects most patients with advanced cancer and significantly worsens quality of life and treatment tolerance. It also retains a niche role in palliative endocrine therapy for advanced hormone-receptor-positive breast and endometrial cancer.<\/p>\n Almindelige:<\/strong> weight gain (the desired effect in cachexia), increased appetite, fluid retention, hyperglycaemia, breakthrough vaginal bleeding, mood changes, insomnia, sweating, hot flushes (paradoxically, in some patients).<\/p>\n Vigtigt:<\/strong><\/p>\nWhat Is Endace?<\/h2>\n
\u2014 det forst\u00e6rker den normale fysiologiske respons snarere end at udl\u00f8se en kunstigt.<\/h2>\n
\n
Dosering og indtagelse<\/h2>\n
\n
\n
Bivirkninger<\/h2>\n
\n
Advarsler<\/h2>\n
\n
L\u00e6gemiddelinteraktioner<\/h2>\n